Human genetic diseases of proteolysis

Human Mutation

Volumn 13, Issue 2, 1999, Pages 87-98

  Kato, Gregory J ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ross Research Building ^*  (United States)

Author keywords

Protease; Proteasome; Proteolysis; Ubiquitin

Indexed keywords

PROTEASOME; PROTEINASE; PROTEINASE INHIBITOR; UBIQUITIN;

BLEEDING DISORDER; DISEASE ASSOCIATION; GENE MUTATION; GENETIC LINKAGE; HUMAN; IMMUNOPATHOLOGY; INBORN ERROR OF METABOLISM; MUSCULAR DYSTROPHY; NEUROLOGIC DISEASE; PANCREATITIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; REVIEW;

CYSTEINE ENDOPEPTIDASES; ENDOPEPTIDASES; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROLYSIS; SERINE ENDOPEPTIDASES;

EUKARYOTA;

EID: 0032936647     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1004(1999)13:2<87::AID-HUMU1>3.0.CO;2-K     Document Type: Review

References (95)

1. Andren L, Dymling JF, Hogeman KE, Wendeberg B. 1962. Osteopetrosis acro-osteolytica: a syndrome of osteopetrosis, acro-osteolysis and open sutures of the skull. Acta Chir Scand 124:496-507.
2. Angelman H. 1965. "Puppet children": a report of three cases. Dev Med Child Neurol 7:681-688.
3. Antonarakis SE, Kazazian HH, Tuddenham EG. 1995. Molecular etiology of factor VIII deficiency in hemophilia A. Hum Mutat 5:1-22.
4. Asakai R, Chung DW, Ratnoff OD, Davie EW. 1989. Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci USA 86:7667-7671.
5. Ashkenazi A, Dixit VM. 1998. Death receptors: Signaling and mechanism. Science 281:1 305-1308.
6. Baumeister W, Walz J, Zuhl F, Seemuller E. 1998. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92:367-380.
7. Biggs R, Douglas AS, Macfarlane RG, Dacie JV, Pitney WR, Merskey C, O'Brien JR. 1952. Christmas disease: a condition previously mistaken tor haemophilia. Brit Med J 2:1378-1382.
8. Board PG, Coggan M, Pidcock ME. 1982. Genetic heterogeneity of human prothrombin (FII) Ann Hum Genet 46:1-9.
9. Botto M, Fong KY, So AK, Rudge A, Walport MJ. 1990. Molecular basis of hereditary C3 deficiency. J Clin Invest 86:1158-1163.
10. Braun L, Schneider PM, Giles CM, Bertrams J, Rittner C. 1990. Null alleles ot human complement C4: evidence for pseudogenes at the C4A locus and for gene conversion at the C4B locus. J Exp Med 171:129-140.
11. Chan CTJ, Clayton-Smith J, Cheng XJ, Buxton J, Webb T, Pembrey ME, Malcolm S. 1993. Molecular mechanisms in Angelman syndrome: a survey of 93 patients. J Med Genet 30:895-902.
12. Chung CS, Morton NE. 1959. Discrimination of genetic entities in muscular dystrophy. Am J Hum Genet 11:339-359.
13. Cicardi M, Igarashi T, Rosen FS, Davis AE III, 1987. Molecular basis tor the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J Clin Invest 79:698-702.
14. Ciechanover A, Schwartz AE. 1998. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 95:2727-2730.
15. Comp PC, Nixon RR, Cooper MR, Esmon CT. 1984. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 74:2082-2088.
16. Cooper DN, Millar DS, Wacey A, Pemberton S, Tuddenham EGD. 1997. Inherited factor X deficiency: molecular genetics and pathophysiology. Thromb Haemost 78:161-172.
17. Croall DE, DeMartino GN. 1991. Calcium-activated neutral protease (calpain) system: Structure, function, and regulation. Physiol Rev 71:813-847.
18. Cuervo AM, Dice JF. 1998. Lysosomes, a meeting point of proteins, chaperones, and proteases. J Mol Med 76:6-12.
19. Dahlhack B. 1997. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol 34:217-234.
20. Day NK, Geiger H, Stroud R, deBracco M, Mancado B, Windhorst DB, Good RA, 1972. C-prime-1r deficiency: an inborn error associated with cutaneous and renal disease. J Clin Invest 51:1102-1108.
21. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg, D. 1992. Complete deficiency of plasminogen-activator inhibitor type I due to a frameshift mutation. New Eng J Med 327:1729-1733.
22. Fay WP, Parker AC, Condrey LR, Shapiro AD. 1997. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 90:204-208.
23. Frederick A, Rolfe M, Chiu MI. 1998. The human UNP locus at 3p21 31 encodes two tissue-selective, cytoplasmic isoforms with deubiquitinating activity that have reduced expression in small cell lung carcinoma cell lines. Oncogene 16:153-165.
24. Furie B, Furie BC. 1992. Molecular and cellular biology of blood coagulation. New Eng J Med 26:800-806.
25. Gelb BD, Shi GP Chapman HA, Desnick RJ. 1996. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238.
26. Giannelli F, Green PM, Sommer SS, Poon M-C, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Figueiredo MS, Brownlce GG. 1997. Haemophilia B: database of point mutations and short additions and deletions, 7th edition. Nucleic Acids Res 25:133-135.
27. Goldberg AL, Akopian TN, Kisselev AF, Lee DH. 1997. Protein degradation by the proteasome and dissection of its in vivo importance with synthetic inhibitors. Mol Biol Rep 24:69-75.
28. Gray DA, Inazawa J, Gupta K, Wong A, Ueda R, Takahashi T. 1995. Elevated expression of Unph, a proto-oncogene at 3p21.3, in human lung tumors. Oncogene 10:2179-2183.
29. Haas AL. 1997. Introduction: evolving roles for ubiquitin in cellular regulation. FASEB J 11:1053-1054.
30. Haas AL, Siepmann TJ. 1997. Pathways of ubiquitin conjugation. FASEB J 11:1257-1268.
31. Hadorn B, Tarlow MJ, Lloyd JK, Wolff OH. 1969. Intestinal enterokinase deficiency. Lancet 1:812-813.
32. Hershko A. 1997. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 9:788-799.
33. Hicke L. 1997. Ubiquitin-dependent internalization and downregulation of plasma membrane proteins. FASEB J 11:1215-1226.
34. Hiemstra PS, Langeler E, Compier B, Keepers Y, Leijh PCJ, van den Barselaar MT, Overbosch D, Daha MR. 1989. Complete and partial deficiencies of complement factor D in a Dutch family. J Clin Invest 84:1957-1961.
35. Hochstrasser M. 1996. Protein degradation or regulation: Ub the judge. Cell 84:813-815.
36. Huibregtse JM, Scheffner M, Howley PM. 1993. Cloning and expression ot the cDNA for E6-AP a protein that mediates the interaction of the human papilloma virus E6 oncoprotein with p53. Mol Cell Biol 13:775-784.
37. Johansson L, Hedner U, Nilsson IM. 1978. A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall. Acta Med Scand 203:477-480.
38. Johnson CA, Densen P, Hurford RK, Jr, Colten HR, Wetsel RA. 1992. Type I human complement C2 deficiency: a 28-base pair gene deletion causes skipping of exon 6 during RNA splicing. J Biol Chem 267:9347-9353.
39. Kingsley CS. 1954. Familial factor V deficiency: the pattern ot heredity. Quart J Med 23:323-329.
40. Kirschke H. 1997. Lysosomal cysteine peptidases and malignant tumours. Adv Exp Med Biol 421:253-257.
41. Kishino T, Lalande M, Wagstaff J. 1997. UBE3A/E6-AP mutations cause Angelman syndrome. Nature Genet 15:70-73.
42. Kitamoto Y, Veile RA, Donis-Keller H, Sadler JE. 1995. cDNA sequence and chromosomal localization of human enterokinase, the proteolytic activator of trypsinogen. Biochemistry 34:4562-4568.
43. Lafreniere RG, Rochefort DL, Chretien N, Rommens JM, Cochius JI, Kalviainen R, Nousiainen LI, Patry G, Farrell K, Soderfeldt B, Federico A, Hale BR, Cossio OH, Sorensen T, Pouliot MA, Kmiec T, Uldall P, Janszky J, Pranzatelli MR, Andermann F, Andermann E, Rouleau GA. 1997. Unstable insertion of the 5-prime flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. Nature Genet 15:298-302.
44. Lalioti MD, Mirotsou M, Buresi C, Peitsch MC, Rossier C, Ouazzani R, Baldy-Moulinier M, Bottani A, Malafosse A, Antonarakis SE. 1997. Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1). Am J Hum Genet 60:342-351.
45. Lane DA, Kunz G, Olds RJ, Thein SL. 1996. Molecular genetics of antithrombin deficiency. Blood Rev 10:59-74.
46. Larsen CN, Finley D. 1997. Protein translocation channels in the proteasome and other proteases. Cell 91:431-434.
47. Li SW, Sieron AL, Fertala A, Hojima Y, Arnold WV, Prockop DJ. 1996. The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previously identified as bone morphogenic protein-1. Proc Nad Acad Sci USA 93:5127-5130.
48. Liddle GW, Bledsoe T, Coppage WS, Jr. 1963. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Phys 76:199-213.
49. Lomas DA, Evans DL, Finch JT, Carrell RW. 1992. The mechanism of Z alpha-1-antitrypsin accumulation in the liver. Nature 357:605-607.
50. Loos M, Heinz HP 1986. Component deficiencies. I. The first component: C1q, C1r, C1s. Prog Allergy 39:212-231.
51. Lundborg HB. 1912. Der Erbgang der progressiven Myoklonusepilepsie (Myoklonie-Epilepsie, Unverricht's familiaere Myoklonie). Z Ges Neurol Psychiat 9:353-358.
52. Marchetti G, Patracchini P, Gemmati D, DeRosa V, Pinotti M, Rodorigo G, Casonate A, Girolami A, Bernardi F. 1992. Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7). Hum Genet 89:497-502.
53. Maroteaux P, Lamy M. 1962. La pycnodysostose. Presse Med 70:999-1002.
54. Maroteaux P, Lamy M. 1965. The malady of Toulouse-Lautrec. JAMA 191:715-717.
55. Matsuura T, Sutclifte JS, Fang P, Galjaard R-J, Jiang Y, Benton CS, Rommens JM, Beaudet AL. 1997. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nature Genet 15:74-77.
56. McAdam RA, Goundis D, Reid KBM. 1988. A homozygous point mutation results in a stop codon in the C1q deficient individual. Immunogenetics 27:259-264.
57. Minor RR, Sippola-Thiele M, McKeon J, Berger J, Prockop DJ. 1986. Defects in the processing of procollagen to collagen are demonstrable in cultured fibroblasts from patients with the Ehlers-Danlos and osteogenesis imperfecta syndromes. J Biol Chem 261:10006-10014.
58. Miyata T, Iwanaga S, Sakata Y, Aoki N. 1982. Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine-600 by threonine in the active site. Proc Natl Acad Sci USA 79:6132-6136.
59. Nilsson IM, Ljungner H, Tengborn L. 1985. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Brit Med J 290:1453-1456.
60. Noyes CM, Griffith MJ, Roberts HR, Lundblad RL. 1983. Identification of the molecular defect in factor IX(Chapel Hill): substitution of histidine for arginine at position 145. Proc Natl Acad Sci USA 80:4200-4202.
61. Nukiwa T, Brantly M, Garver R, Paul L, Courtney M, LeCocq J-P, Crystal RG. 1986. Evaluation of "at risk" alpha-1-antitrypsin genotype SZ with synthetic oligonucleotide gene probes. J Clin Invest 77:528-537.
62. O'Brien DP Gale KM, Anderson JS, McVey JH, Miller GJ, Meade TW, Tuddenham EGD. 1991. Purification and characterization of factor VII 304-gln: a variant molecule with reduced activity isolated from a clinically unaffected male. Blood 78:132-140.
63. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolte M. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685.
64. Pagano M. 1997. Cell cycle regulation by the ubiquitin pathway. FASEB J 11:1067-1075.
65. Pennacchio LA, Lehesjoki A-E, Stone NE, Willour VL, Virtaneva K, Miao J, D'Amato E, Ramirez L, Faham M, Koskiniemi M, Warrington JA, Norio R, de la Chapelle A, Cox DR, Myers RM. 1996. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 271:1731-1734.
66. Perry DJ, Carrell RW. 1996. Molecular genetics of human antithrombin deficiency. Hum Mutat 7:7-22.
67. Pickart CM. 1997. Targeting of substrates to the 26S proteasome. FASEB J 11:1055-1066.
68. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. 1996. A common genetic variation in the 3-prime-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698-3703.
69. Reddy SV, Zhou Z-Q, Rao KJ, Scott JR Watzke H, High KA, Jagadeeswaran P. 1989. Molecular characterization of human factor X (San Antonio). Blood 74:1486-1490.
70. Reitsma PH. 1996. Protein C deficiency: summary of the 1995 database update. Nucleic Acids Res 24:157-159.
71. Richard I, Bronx O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N, Brenguier L, Devaud C, Pasturaud P, Roudaut C, Hillaire D, Passos-Bueno M-R, Zatz M, Tischtield JA, Fardeau M, Jackson CE, Cohen D, Beckmann JS. 1995. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 81:27-40.
72. Richard I, Brenguier L, Dincer P, Roudaut C, Bady B, Burgunder JM, Chemaly R, Garcia CA, Halaby G, Jackson CE, Kurnit DM, Lefranc G, Legum C, Loiselet J, Merlini L, Nivelon-Chevallier A, Ollagnon-Roman E, Restagno G, Topaloglu H, Beckmann JS. 1997. Multiple independent molecular etiology tor limb-girdle muscular dystrophy type 2A patients from various geographical origins. Am J Hum Genet 60:1128-1138.
73. Romeo G, Hassan HJ, Staempfli S, Roncuzzi L, Cianetti L, Leonardi A, Vicente V, Mannucci PM Bertina R, Peschle C, Cortese R. 1987. Hereditary thrombophilia: identification of nonsense and missense mutations in the protein C gene. Proc Natl Acad Sci USA 84:2829-2832.
74. Saitoh S, Harada N, Jinno Y, Hashimoto K, Imaizumi K, Kuroki Y, Fukushima Y, Sugimoto T, Renedo M, Wagstaff J, Lalande M, Mutirangura A, Kuwano A, Ledbetter, DH, Niikawa N. 1994. Molecular and clinical study of 61 Angelman syndrome patients. Am J Med Genet 52:158-163.
75. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papilloma virus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
76. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
77. Schmidt M, Kloetzel P-M. 1997. Biogenesis of eukaryotic 20S proteasomes: the complex maturation pathway of a complex enzyme. FASEB J 11:1235-1243.
78. Shimkets RA, Warnock DO, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR, Jr, Ulick S, Milora RV, Findling JW, Canessa CM, Rossier BC, Litton RE 1994. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79:407-414.
79. Shyur SD, Hill HR. 1996. Recent advances in the genetics of primary immunodeficiency syndromes. J Pediatr 129:8-24.
80. Slingsby JH, Norsworthy P, Pearcc G, Vaishnaw AK, Issler H, Morley BJ, Walport MJ. 1996. Homozygous hereditary C1q deficiency and systemic lupus erythematosus: a new family and the molecular basis of C1q deficiency in three families. Arthritis Rheum 39:663-670.
81. Sommer T, Wolf DH. 1997. Endoplasmic reticulum degradation: reverse protein flow of no return. FASEB J 11:1227-1233.
82. Staub O, Dho S, Henry P, Correa J, Ishikawa T, McGlade J, Rotin D. 1996. WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome. EMBO J 15:2371-2380.
83. Stoppa-Lyonnet D, Tosi M, Laurent J, Sobel A, Lagrue G, Meo T. 1987. Altered C1 inhibitor genes in type I hereditary angioedema. New Eng J Med 317:1-6.
84. Thornberry NA, Lazebnik Y. 1998. Caspases: Enemies within. Science 281:1312-1316.
85. Topaloglu R, Bakkaloglu A, Slingsby JH, Mihatsch MJ, Pascual M, Norsworthy P, Morley BJ, Saatci U, Schifferli JA, Walport MJ. 1996. Molecular basis of hereditary C1q deficiency associated with SLE and IgA nephropathy in a Turkish family. Kidney Int 50:635-642.
86. Townes PL. 1972. Trypsinogen deficiency and other proteolytic deficiency diseases. Birth Defects Orig Art Ser VIII (2): 95-101.
87. Villa P, Kaufmann SH, Earnshaw WC. 1997. Caspases and caspase inhibitors. Trends Biochem Sci 22:388-393.
88. Virtaneva K, D'Amato E, Miao J, Koskiniemi M, Norio R, Avanzini G, Franceschetti S, Michelucci R, Tassinari CA, Omer S, Pennacchio LA, Myers RM, Dieguez-Lucena JL, Krahe R, de la Chapelle A, Lehesjoki A-E. 1997. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nature Genet 15:393-396.
89. Weitz JI, Silverman EK, Thong B, Campbell EJ. 1992. Plasma levels ot elastase-specitic fibrinopeptides correlate with proteinase inhibitor phenotype: evidence for increased elastase activity in subjects with homozygous and heterozygous deficiency of alpha-1-proteinase inhibitor. J Clin Invest 89:766-773.
90. Westberg J, Fredrikson GN, Truedsson L, Sjoholm AG, Uhlen M. 1995. Sequence-based analysis of properdin deficiency: identification of point mutations in two phenotypic forms ot an X-linked immunodeficiency. Genomics 29:1-8.
91. Whaley K, Schwaeble W. 1997. Complement and complement deficiencies. Semin Liver Dis 17:297-310.
92. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, Martin SP, Gates LK, Jr, Amann ST, Toskes PP, Liddle R, McGrath K, Uomo G, Post JC, Ehrlich GD. 1996. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nature Genet 14:141-145.
93. Wilkinson KD. 1997. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 11:1245-1256.
94. Winkelstein JA, Colten HR. 1989. Genetically determined disorders of the complement system. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease, 6th edition. New York: McGraw-Hill. p 2711-2737.
95. Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH. 1994. A lag in intracellular degradation of mutant alpha-1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha-1-antitrypsin deficiency. Proc Natl Acad Sci USA 91:9014-9018.